Thomas Thompson, PhD, Associate Professor Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati College of Medicine
Dr. Thompson is an expert in structural biology and has determined structures for molecules of interest to Fairbanks Pharmaceuticals research program. He and Dr. Schneyer have collaborated for several years on structural aspects of FSTL3 binding to activin and related growth factors that will be important for designing novel therapeutics.

Andrew Stewart, MD, Professor of Medicine, Endocrinology, Diabetes and Bone Disease and Director, Diabetes Obesity And Metabolism Institute, Mt Sinai Hospital
Dr. Stewart has made major contributions to understanding of regulation of beta cell proliferation in rodents and in humans. He has recently discovered small molecules that enhance human beta cell proliferation as potential novel diabetes treatments. Dr. Stewart has broad knowledge of beta cell biology as well as a deep clinical understanding of gaps in current diabetes treatments and will advise Fairbanks Pharmaceuticals on its therapeutic development program.

Daniel Bernard, PhD, Professor of Pharmacology and Therapeutics, McGill University
Dr. Bernard has elucidated the role of activin and related growth factors in control of reproductive hormone synthesis and secretion. He is an expert in the biochemistry, molecular biology, and genetics of the entire signaling system in this family of growth factors and his expertise will be valuable in determining mechanisms and optimizing function of Fairbanks Pharmaceuticals’ therapeutic candidates.

Laura Alonso, MD, Associate Professor of Medicine and Director of Beta Cell Biological Studies, University of Massachusetts Medical School
In addition to her clinical activities with diabetes patients, Dr. Alonso has an NIH-funded laboratory focused on mechanisms regulating beta cell function and proliferation. She and Dr. Schneyer have collaborated on several proposals to examine the mechanisms of activin action in regulating beta cell function. In addition, her expertise with mouse models of diabetes and insulin resistance makes her an excellent advisor for designing tests of candidate therapeutics developed by Fairbanks Pharmaceuticals.

Randall Whitcomb MD, Senior Advisor at Frazier Healthcare Partners
Dr. Whitcomb has more than 35 years of experience as an endocrinologist, Chief Medical Officer for large pharma, and was involved with a number of biotech companies assisting with clinical trial design and regulatory approval strategies. He serves as a long-range planning advisor for Fairbanks Pharmaceuticals as well as a connection to potential partners.